Bronchopulmonary dysplasia at 28 days · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 28 days compared with placebo or control (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 36 weeks' gestation compared with placebo or control (low certainty).
1 finding from 1 review
All‐cause neonatal mortality before hospital discharge · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in all‐cause neonatal mortality before hospital discharge compared with placebo or control (moderate certainty).
1 finding from 1 review
Proportion of infants requiring surgical ligation of PDA · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in proportion of infants requiring surgical ligation of PDA compared with placebo or control (moderate certainty).
1 finding from 1 review
NEC ≥ stage II · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in NEC (≥ Bell stage 2) compared with placebo or control (low certainty).
1 finding from 1 review
Mucocutaneous or gastrointestinal bleeding · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in mucocutaneous or gastrointestinal bleeding compared with placebo or control (low certainty).
1 finding from 1 review
Disease response · psoriatic arthritis
Methotrexate may leads to higher disease response compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life ‐ not measured · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review
Disease activity ‐ not measured · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review
Change in radiographic progression ‐ not measured · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events (leflunomide) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Withdrawals due to adverse events · psoriatic arthritis
2 findings from 1 review
Serious adverse events (ciclosporin A) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Function · psoriatic arthritis
1 finding from 1 review
Health‐related quality of life ‐ not reported · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review
Disease activity · psoriatic arthritis
1 finding from 1 review
Change in radiographic progression ‐ not measured · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · psoriatic arthritis
Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · psoriatic arthritis
Methotrexate showed no clear difference in withdrawals due to adverse events (WAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Disease response (leflunomide) · psoriatic arthritis
It is very uncertain whether methotrexate changes disease response (leflunomide) compared with other DMARDs (very low certainty).
1 finding from 1 review